Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market by Product Type (DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (Tetanus and Diphtheria) vaccine, and Tdap (Tetanus-Diphtheria-Acellular Pertussis) vaccine, by Age Group (Adult and Pediatric), and by End User (Hospitals, Clinics, and Vaccination Centers): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL3931799
- 193 Pages
- May 2020
- Medical Devices
Diphtheria, tetanus, and pertussis or DTP, are serious diseases caused by bacteria. DTP vaccine is a blend of diphtheria and tetanus toxoids adsorbed with pertussis vaccine for intramuscular vaccination. Diphtheria and tetanus toxoids and pertussis vaccine are recommended simultaneously for successful immunization of children up to seven years of age against diphtheria, tetanus, and pertussis (whooping cough) provide an impactful boost to the market growth. Approximately 86 % of infants worldwide (116.3 million children) received 3 doses of diphtheria-tetanus-pertussis 3 (DTP3) vaccine during 2018, shielding them from infectious diseases that may cause severe illness and disability, or could even be fatal. .
In 2017, the global demand for all D&T containing vaccines was estimated at around 945 million doses. Self-procuring countries represent almost half of the global demand for DTP vaccines. The WHO has recommended a life course of six doses of diphtheria and tetanus containing vaccines throughout the world. Thus, established firms are currently devoting almost 5% of their total R&D expenditure in vaccine development. Since last decade, biotech firms have emerged as a new force in the area of early stage product development and applied vaccine research. Players operating in the DTP vaccines market are mostly focused on establishing a strong network with dealers and their distributors. Players are partnering with other vaccine manufacturing companies to enhance their product portfolio as well as to expand their global reach. Vaccine development technology has witnessed a revolutionary growth, and has led to the expansion of innovative and new diagnostic technologies with various advancements in therapeutic applications.
The report classifies the global DTP vaccines market based on products, age group, end users, and region. By product, it is categorized into a DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (tetanus and diphtheria) vaccine, and Tdap (Tetanus-diphtheria-acellular Pertussis vaccine). By age group, it is divided into adult and pediatric. By end users, it is categorized into hospitals, clinics, and vaccination centers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
ü This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
ü An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
ü A comprehensive analysis of the factors that drive and restrain the growth of the global DTP Vaccine market is provided.
ü An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
• By Product Type
o DTaP
o TD
o Tdap
• By Age Group
o Adult
o Pediatric
• By End User
o Hospitals
o Clinics
o Vaccination Centers
• By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• Germany
• France
• UK
• Italy
• Rest of Europe
o Asia-Pacific
• Japan
• China
• Australia
• India
• Rest of Asia-Pacific
o LAMEA
• Brazil
• South Africa
• Rest of LAMEA
KEY MARKET PLAYERS
• AJ Vaccines
• Bionet-Asia
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Massbiologics
• Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
• Merck & Co., Inc.
• Panacea Biotec Ltd.
• Sanofi
• Serum Institute of India Pvt. Ltd
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top player positioning, 2019
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in initiatives by pharma companies to enhance vaccine R&D
3.4.1.2.Growth in awareness among people about the advantages of DTP vaccines
3.4.2.Restraints
3.4.2.1.Inadequate access to vaccines in under developed countries
3.4.2.2.High cost of vaccine development
3.4.3.Opportunities
3.4.3.1.Innovative vaccine technologies
CHAPTER 4:DTP VACCINES MARKET, BY PRODUCT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.DTaP Vaccines
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.TD Vaccines
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Tdap Vaccines
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:DTP VACCINES MARKET, BY AGE GROUP
5.1.Overview
5.1.1.Market size and forecast
5.2.Adults
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Pediatrics
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6:DTP VACCINES MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Clinics
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Vaccination Centers
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:DTAP VACCINES MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by product
7.2.3.Market size and forecast, by age group
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S. market size and forecast, by product
7.2.5.2.U.S. market size and forecast, by age group
7.2.6.Market size and forecast, by end users
7.2.6.1.Canada market size and forecast, by product
7.2.6.2.Canada market size and forecast, by age group
7.2.7.Market size and forecast, by end users
7.2.7.1.Mexico market size and forecast, by product
7.2.7.2.Mexico market size and forecast, by age group
7.2.8.Market size and forecast, by end users
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by product
7.3.3.Market size and forecast, by age group
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany market size and forecast, by product
7.3.5.2.Germany market size and forecast, by age group
7.3.6.Market size and forecast, by end users
7.3.6.1.France market size and forecast, by product
7.3.6.2.France market size and forecast, by age group
7.3.7.Market size and forecast, by end users
7.3.7.1.UK market size and forecast, by product
7.3.7.2.UK market size and forecast, by age group
7.3.8.Market size and forecast, by end users
7.3.8.1.Italy market size and forecast, by product
7.3.8.2.Italy market size and forecast, by age group
7.3.9.Market size and forecast, by end users
7.3.9.1.Rest of Europe market size and forecast, by product
7.3.9.2.Rest of Europe market size and forecast, by age group
7.3.10.Market size and forecast, by end users
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by product
7.4.3.Market size and forecast, by age group
7.4.4.Market size and forecast, by end users
7.4.5.Market size and forecast, by country
7.4.5.1.Japan market size and forecast, by product
7.4.5.2.Japan market size and forecast, by age group
7.4.6.Market size and forecast, by end users
7.4.6.1.China market size and forecast, by product
7.4.6.2.China market size and forecast, by age group
7.4.7.Market size and forecast, by end users
7.4.7.1.Australiamarket size and forecast, by product
7.4.7.2.Australia market size and forecast, by age group
7.4.8.Market size and forecast, by end users
7.4.8.1.India market size and forecast, by product
7.4.8.2.India market size and forecast, by age group
7.4.9.Market size and forecast, by end users
7.4.9.1.Rest of Asia Pacificmarket size and forecast, by product
7.4.9.2.Rest of Asia Pacific market size and forecast, by age group
7.4.10.Market size and forecast, by end users
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by product
7.5.3.Market size and forecast, by age group
7.5.4.Market size and forecast, by end users
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil market size and forecast, by product
7.5.5.2.Brazil market size and forecast, by age group
7.5.6.Market size and forecast, by end users
7.5.6.1.South Africa market size and forecast, by product
7.5.6.2.South Africa market size and forecast, by age group
7.5.7.Market size and forecast, by end users
7.5.7.1.Rest of LAMEA market size and forecast, by product
7.5.7.2.Rest of LAMEA market size and forecast, by age group
7.5.8.Market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.AJ VACCINES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.2.BIONET-ASIA
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.3.GLAXOSMITHKLINE PLC (GSK)
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.JOHNSON & JOHNSON
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.MASSBIOLOGICS
8.5.1.Company overview
8.5.2.Company snapshot1
8.5.3.Product portfolio
8.6.MEIJI HOLDINGS CO., LTD. (KM BIOLOGICS CO., LTD.)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.MERCK & CO., INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.PANACEA BIOTEC LTD.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.SANOFI
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.SERUM INSTITUTE OF INDIA PVT. LTD
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
TABLE 01.GLOBAL DTP VACCINES MARKET, BY PRODUCT TYPE 2019–2027, ($MILLION)
TABLE 02.DTAP VACCINES MARKET, BY REGION, 2019–2027, ($MILLION
TABLE 03.TD VACCINES MARKET, BY REGION, 2019–2027, ($MILLION)
TABLE 04.TDAP VACCINES MARKET, BY REGION, 2019–2027, ($MILLION)
TABLE 05.GLOBAL DTP VACCINES MARKET, BY AGE GROUP, 2019–2027, ($MILLION)
TABLE 06.DTP VACCINES MARKET FOR ADULTS, BY REGION, 2019–2027, ($MILLION)
TABLE 07.DTP VACCINES MARKET FOR PEDIATRICS, BY REGION, 2019–2027, ($MILLION)
TABLE 08.GLOBAL DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 09.DTP MARKET FOR HOSPITALS, BY REGION, 2019–2027, ($MILLION)
TABLE 10.DTP MARKET FOR CLINICS, BY REGION, 2019–2027, ($MILLION)
TABLE 11.DTP MARKET FOR VACCINATION CENTERS, BY REGION, 2019–2027, ($MILLION)
TABLE 12.DTP VACCINES MARKET, BY REGION 2019–2027, ($MILLION)
TABLE 13.NORTH AMERICA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 14.NORTH AMERICA VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 15.NORTH AMERICA VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 16.NORTH AMERICA DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 17.U.S. DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 18.U.S. DTAP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 19.U.S. DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 20.CANADA DTP VACCINES MARKET, BY PRODUCT, 2019-2026, ($MILLION)
TABLE 21.CANADA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 22.CANADA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 23.MEXICO DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 24.MEXICO DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 25.MEXICO DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 26.EUROPE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 27.EUROPE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 28.EUROPE DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 29.EUROPE DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 30.GERMANY DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 31.GERMANY DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 32.GERMANY DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 33.FRANCE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 34.FRANCE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 35.FRANCE DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 36.UK DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 37.UK DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 38.UK DTP VACCINES MARKET, BY END USER, , 2019-2027, ($MILLION)
TABLE 39.ITALY DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 40.ITALY DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 41.ITALY DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 42.REST OF EUROPE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 43.REST OF EUROPE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 44.REST OF EUROPE DTAP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 45.ASIA-PACIFIC DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 46.ASIA-PACIFIC DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 47.ASIA-PACIFIC DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 48.ASIA-PACIFIC DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 49.JAPAN DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 50.JAPAN DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 51.JAPAN DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 52.CHINA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 53.CHINA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 54.CHINA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 55.AUSTRALIADTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 56.AUSTRALIA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 57.AUSTRALIADTAP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 58.INDIADTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 59.INDIADTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 60.INDIADTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 61.REST OF ASIA PACIFICDTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 62.REST OF ASIA PACIFICDTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 63.REST OF ASIA PACIFICDTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 64.LAMEA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 65.LAMEA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 66.LAMEA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 67.LAMEA DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 68.BRAZIL DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 69.BRAZIL DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 70.BRAZIL DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 71.SOUTH AFRICA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 72.SOUTH AFRICA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 73.SOUTH AFRICA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 74.REST OF LAMEA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 75.REST OF LAMEA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 76.REST OF LAMEA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 01.AJ VACCINES: COMPANY SNAPSHOT
TABLE 02.AJ VACCINE: PRODUCT PORTFOLIO
TABLE 03.BIONET-ASIA: COMPANY SNAPSHOT
TABLE 04.BIONET-ASIA: PRODUCT PORTFOLIO
TABLE 05.GSK: COMPANY SNAPSHOT
TABLE 06.GLAXOSMITHKLINE PLC.: OERATING SEGMENT
TABLE 07.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 08.J&J: COMPANY SNAPSHOT
TABLE 09.J&J: OPERATING SEGMENTS
TABLE 10.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 11.MASSBIOLOGICS: COMPANY SNAPSHOT
TABLE 12.MASSBIOLOGICS: PRODUCT PORTFOLIO
TABLE 13.MEIJI.: COMPANY SNAPSHOT
TABLE 14.MEIJI HOLDINGS CO., LTD..: OPERATING SEGMENTS
TABLE 15.MEIJI HOLDINGS CO., LTD.: PRODUCT PORTFOLIO
TABLE 16.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 17.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 18.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 19.PANACEA BIOTEC LTD..: COMPANY SNAPSHOT
TABLE 20.PANACEA BIOTEC LTD..: OPERATING SEGMENTS
TABLE 21.PANACEA BIOTEC LTD.: PRODUCT PORTFOLIO
TABLE 22.PANACEA BIOTEC LTD..: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 23.SANOFI: COMPANY SNAPSHOT
TABLE 24.SANOFI: OERATING SEGMENT
TABLE 25.SANOFI: PRODUCT PORTFOLIO
TABLE 26.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 27.SII.: COMPANY SNAPSHOT
TABLE 28.SII.: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
